Zydus Lifesciences Gets US FDA Nod For Parkinson's Disease Drug

Zydus Lifesciences Ltd. announced on Wednesday that the company has received approval from the United States Food and Drug Administration to market a generic medication to treat Parkinson's disease.

The company has received approval from the US FDA to market Amantadine extended-release capsules (68.5 mg) and tentative approval for Gocovri (137 mg) capsules, the drug firm said in a statement.

Amantadine extended-release capsules are designed to treat dyskinesia in Parkinson's disease patients, as per the company's statement.

Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ-III, Zydus Lifesciences said.

This approval makes Zydus eligible for 180 days of exclusivity for Amantadine extended-release capsules (68.5 mg), it added.

The Gujarat-based group said it now has 400 approvals from the US FDA.

Shares of Zydus Lifesciences closed 2.17% higher at Rs 1,138.05 per share, as compared to a 0.09% advance in the BSE Sensex.

(With inputs from PTI)

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.